RPG Life Sciences Limited

BSE: RPGLIFE532983ISIN INE105J01010

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹2,602.35+66.05 (+2.60%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹3,130.50
52W low: ₹1,731.25
Off 52W high: -16.87%
1M return: -10.03%
3M return: -3.98%
6M return: +9.06%
1Y return: +5.41%
20D avg volume: 1,448
50 DMA: ₹2,770.04
200 DMA: ₹2,377.49

Key ratios Consolidated

Market cap: ₹4,304 Cr
Current price: ₹2,602.35
52W high / low: ₹3,130.50 / ₹1,731.25
Face value: ₹8.00
P/E: 38.77
P/B: 6.26
EPS (TTM): ₹67.12
Book value / share: ₹415.55
ROE: —
ROCE: 24.50%
Operating margin: —
Net margin: —
Debt / equity: 0.03
Net debt: ₹-130.46 Cr
Interest cover: 174.26
Dividend yield: 0.92%
Dividend / share (TTM): ₹24.00
Payout: 35.76%
Cash conversion cycle: 74.0 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q4 FY25
Income statement
	211.64	195.69	176.89	180.03	—
	4.26	4.70	12.40	3.41	—
	215.90	200.39	189.29	183.44	—
	178.86	158.93	150.19	145.90	—
	24.10	37.68	36.43	34.79	—
	58.72	39.53	22.63	43.63	—
	44.09	37.76	36.30	35.32	—
	0.84	0.63	0.39	0.25	—
	6.80	5.90	5.74	5.38	—
	54.99	46.49	47.17	40.05	—
	37.04	41.46	39.10	37.54	—
	0.00	0.00	1.10	-8.42	—
	37.04	41.46	40.20	29.12	—
	8.82	10.70	10.30	6.99	—
	28.22	30.76	29.90	22.13	—
	17.07	18.60	18.08	13.38	—
Key metrics
	44.68	47.99	46.33	34.75	—
	21.10%	24.50%	26.20%	19.30%	—
	13.30%	15.70%	16.90%	12.30%	—
	4.30%	—	6.40%	—	—

Metric	TTM	FY26	FY25
Income statement
	764.25	707.52	—
	24.77	25.58	—
	789.02	733.10	—
	633.88	582.80	—
	133.00	135.98	—
	164.51	138.10	—
	153.47	141.48	—
	2.11	0.89	—
	23.82	21.48	—
	188.70	166.86	—
	155.14	150.30	—
	-7.32	3.90	—
	147.82	154.20	—
	36.81	39.03	—
	111.01	115.17	—
	67.13	18.08	—
Key metrics
	173.75	176.57	—
	22.73%	25.00%	—
	14.53%	16.30%	—
	—	24.50%	—
	—	-8.86	—
	—	0.49	—
	—	0.03	—
	—	-130.46	—
	—	74.0	—
Balance sheet
	—	793.15	—
	—	564.75	—
	—	150.46	—
	—	116.68	—
	—	123.84	—
	—	191.70	—
	—	97.21	—
	—	160.53	—
	—	20.00	—
	—	6.67	—
	—	13.33	—
	—	605.38	—
Cash flow
	—	56.50	—
	—	85.84	—
	—	-20.58	—
	—	65.36	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	193.39	195.69	176.89	180.03	181.68	168.92	143.09	172.71	172.21	165.42	126.99	153.70
	3.77	4.16	12.36	3.41	4.54	5.23	5.06	3.31	1.94	2.37	1.65	1.92
	197.16	199.85	189.25	183.44	186.22	174.15	148.15	176.02	174.15	167.79	128.64	155.62
	167.08	158.64	150.15	145.90	147.99	138.72	123.15	129.13	131.76	131.79	110.90	120.08
	23.69	37.68	36.43	34.79	32.72	32.04	26.89	30.19	20.81	32.37	28.03	24.85
	40.83	39.53	22.63	43.63	38.78	33.06	21.22	22.70	26.33	24.89	14.92	16.49
	39.61	37.76	36.30	35.32	36.16	33.70	31.60	28.71	33.09	32.74	32.08	33.69
	0.78	0.63	0.39	0.25	0.12	0.13	0.18	0.12	0.17	0.15	0.14	0.14
	5.56	5.90	5.74	5.38	5.22	5.14	5.37	5.46	5.31	5.29	4.49	4.14
	50.85	46.20	47.13	40.05	39.91	39.73	37.28	38.73	39.02	38.60	32.75	33.94
	30.08	41.21	39.10	37.54	38.23	35.43	25.00	46.89	42.39	36.00	17.74	35.54
	0.00	0.00	1.10	-8.42	11.22	0.00	109.90	—	-27.30	—	—	—
	30.08	41.21	40.20	29.12	49.45	35.43	134.90	46.89	15.09	36.00	17.74	35.54
	6.79	10.64	10.30	6.99	12.60	9.14	17.55	11.96	10.89	9.24	4.50	9.08
	23.29	30.57	29.90	22.13	36.85	26.29	117.35	34.93	4.20	26.76	13.24	26.46
	14.08	18.49	18.08	13.38	22.28	15.90	70.96	21.12	2.54	16.18	8.01	16.00
Key metrics
	36.42	47.74	46.33	34.75	54.79	40.70	140.45	52.47	20.57	41.44	22.37	39.82
	18.80%	24.40%	26.20%	19.30%	30.20%	24.10%	98.20%	30.40%	11.90%	25.10%	17.60%	25.90%
	12.00%	15.60%	16.90%	12.30%	20.30%	15.60%	82.00%	20.20%	2.40%	16.20%	10.40%	17.20%
	4.90%	—	6.40%	—	8.80%	—	25.10%	—	—	—	—	—
	6.40%	15.80%	23.60%	4.20%	5.50%	2.10%	12.70%	12.40%	—	—	—	—
	-36.80%	16.30%	-74.50%	-36.60%	777.40%	-1.80%	786.30%	32.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	746.00	707.52	653.43	582.05	512.81	440.16
	23.70	25.54	12.68	7.21	4.80	2.99
	769.70	733.06	666.11	589.26	517.61	443.15
	621.77	582.76	515.83	471.42	425.93	369.98
	132.59	135.98	110.26	120.65	86.12	88.13
	146.62	138.10	95.14	61.18	92.05	78.90
	148.99	141.48	126.14	132.15	117.06	99.97
	2.05	0.89	0.62	0.45	0.31	0.52
	22.58	21.48	21.43	17.07	15.50	15.66
	184.23	166.82	153.63	137.22	122.19	112.01
	147.93	150.30	150.28	117.84	91.68	73.17
	-7.32	3.90	82.60	—	—	—
	140.61	154.20	232.88	117.84	91.68	73.17
	34.72	39.03	49.64	30.18	24.04	21.69
	105.89	115.17	183.24	87.66	67.64	51.48
	64.03	69.64	110.80	53.01	40.90	31.13
Key metrics
	165.24	176.57	254.93	135.36	107.49	89.35
	22.15%	25.00%	39.00%	23.30%	21.00%	20.30%
	14.19%	16.30%	28.00%	15.10%	13.20%	11.70%
	—	24.50%	43.40%	—	—	—
	11.94%	8.30%	12.30%	13.50%	16.50%	—
	-50.84%	-37.10%	109.00%	29.60%	31.40%	—
	—	-8.86	41.83	—	—	—
	—	0.49	0.42	—	—	—
	—	0.03	0.00	—	—	—
	—	-95.68	-28.70	—	—	—
	—	74.0	56.1	—	—	—
Balance sheet
	—	793.15	657.81	—	—	—
	—	529.96	466.81	—	—	—
	—	115.68	28.70	—	—	—
	—	116.68	86.76	—	—	—
	—	123.84	92.98	—	—	—
	—	—	14.21	—	—	—
	—	191.70	161.18	—	—	—
	—	97.21	79.39	—	—	—
	—	160.53	119.83	—	—	—
	—	20.00	0.00	—	—	—
	—	6.67	0.00	—	—	—
	—	13.33	0.00	—	—	—
	—	605.38	530.53	—	—	—
Cash flow
	—	56.50	77.86	—	—	—
	—	51.06	-41.80	—	—	—
	—	-20.58	-27.08	—	—	—
	—	65.36	36.03	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +11.33%
Sales CAGR 5Y: —
Profit CAGR 3Y: +19.41%
Profit CAGR 5Y: —
Sales YoY (TTM): +11.94%
Profit YoY (TTM): -50.84%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 72.94%

Quarter	September 2026	June 2026
Promoter %	72.94%	72.94%

Holder	Type	Holding	Previous	Change
Nucleus Life Trust (Mr. Harsh Vardhan Goenka is a Trustee)	Promoter Group	53.94%	53.94%	0.00%
Ektara Enterprises Llp	Promoter Group	15.57%	15.57%	0.00%
CLARUS CAPITAL I	Public	6.56%	5.59%	+0.97%
Stel Holdings Limited	Promoter Group	3.18%	3.18%	0.00%
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED	Public	2.02%	2.02%	0.00%
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS	Public	1.08%	1.10%	-0.02%
Harshvardhan Goenka	Promoter	0.16%	0.16%	0.00%
Mala Goenka	Promoter	0.05%	0.05%	0.00%
Carniwal Investments Limited	Promoter Group	0.04%	0.04%	0.00%
Sofreal Mercantrade Pvt Ltd	Promoter Group	0.00%	0.00%	0.00%
Prism Estates Trust (Mr. Harsh Vardhan Goenka is a Trustee )	Promoter Group	0.00%	0.00%	0.00%
Vayu Associates Llp	Promoter Group	0.00%	0.00%	0.00%
RG Family Trust (Mr. Anant Vardhan Goenka is a Trustee)	Promoter Group	0.00%	0.00%	0.00%
AVG Family Trust (Mr. Anant Vardhan Goenka is aTrustee )	Promoter Group	0.00%	0.00%	0.00%
Malabar Coastal Holdings Llp	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
RPG Life Sciences Limited S	4,304	2,602.35	40.65	24.50%	+11.94% TTM	-50.84% TTM	+5.41%

Filings & corporate actions

Recent announcements

Newspaper publication31 Oct 2026 · Company Update / Newspaper Publication
Audio Recording of Q2FY27 Results Earnings Call held on October 30, 202630 Oct 2026 · Company Update / Analyst / Investor Meet
Investor Presentation29 Oct 2026 · Company Update / Investor Presentation
Amendment to Policy on Related Party Transactions29 Oct 2026 · Company Update / General
Press Release29 Oct 2026 · Company Update / Press Release / Media Release
Financial Result for the quarter ended September 30, 202629 Oct 2026 · Result / Financial Results
Outcome of Board Meeting29 Oct 2026 · Board Meeting / Outcome of Board Meeting
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and any other applicable provisions, please note the schedule of earnings call ....23 Oct 2026 · Company Update / Analyst / Investor Meet
RPG Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve unaudited financial results ....22 Oct 2026 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 20188 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Newspaper advertisement in respect to Special window opened for lodgment of transfer and dematerialization request(s).30 Sep 2026 · Company Update / Newspaper Publication
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Clarus Capital I, Others28 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Intimation for Scheme of Amalgamation of Actis Generics Private Limited and their respective shareholders under section 230 to 232 and other applicable provisions of the Companies Act, 2013.26 Sep 2026 · Company Update / General
Closure of Trading Window25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
update on share purchase agreement dated July 29, 2026 with Actis Generics Private Limited24 Sep 2026 · Company Update / General
Clarification for Volume Movement Letter24 Sep 2026 · Company Update / General
The Exchange has sought clarification from RPG Life Sciences Ltd on September 24, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.24 Sep 2026 · Company Update / Clarification
Intimation of Analysts/Institutional Investors Meet17 Sep 2026 · Company Update / Analyst / Investor Meet
Update on completion of BTA execution by RPG Active Pharma Limited with Raghava Life Sciences Private Limited15 Sep 2026 · Company Update / General
update on Investment and Shareholders Agreement entered on July 29, 2026, subsidiary of the company allotted securities to the Investors.9 Sep 2026 · Company Update / General
Update on Analyst/Institutional call4 Sep 2026 · Company Update / General
Intimation of Investor meet dial in details3 Sep 2026 · Company Update / General
Investors Presentation2 Sep 2026 · Company Update / Investor Presentation
Schedule of Investors Meet2 Sep 2026 · Company Update / Analyst / Investor Meet
Press Release2 Sep 2026 · Company Update / Press Release / Media Release
Intimation of execution of Business Transfer Agreement by RPG Active Pharma Limited (WOS) with Raghava Life Sciences Private Limited for Acquisition of API Business.2 Sep 2026 · Company Update / General
Outcome of Board Meeting2 Sep 2026 · Company Update / General
Cancellation of Investor meet1 Sep 2026 · Company Update / General
The Company has informed about the Schedule of Analyst/Institutional Investors Meet25 Aug 2026 · Company Update / Analyst / Investor Meet
The Company has informed about the Schedule of Analyst/Institutional Investors Meet20 Aug 2026 · Company Update / Analyst / Investor Meet
Resignation of Senior Management Personnel15 Aug 2026 · Company Update / Cessation
Completion of transactions in API Business Transfer Agreement with RPG Active Pharma Limited.15 Aug 2026 · Company Update / General
RPG Life Sciences Limited has informed the Exchange about the Further investment in RPG Active Pharma Limited15 Aug 2026 · Company Update / General
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the details of the Analyst/Institutional ....10 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation on superannuation of Senior Management Personnel31 Jul 2026 · Company Update / Change in Management
Newspaper advertisement in respect to Special window opened for lodgement of transfer and dematerialization request(s).31 Jul 2026 · Company Update / Newspaper Publication
Press Release29 Jul 2026 · Company Update / Press Release / Media Release
Execution of Share Purchase Agreement29 Jul 2026 · Company Update / Acquisition
Execution of Business Transfer Agreement29 Jul 2026 · Company Update / Restructuring
Outcome of Board Meeting held today July 29, 202629 Jul 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 24.0000	9 Jul 2026	9 Jul 2026	—
Special Dividend - Rs. - 4.0000	27 Jun 2025	27 Jun 2025	—
Final Dividend - Rs. - 20.0000	27 Jun 2025	27 Jun 2025	—
Final Dividend - Rs. - 16.0000	28 Jun 2024	28 Jun 2024	—

Board meetings

29 Oct 2026 Board Meeting - Financial Results
28 Jul 2026 Board Meeting - Financial Results